Ophthalmic centre Moorfields Eye Hospital Dubai (Moorfields) disclosed on Sunday that it has appointed Dr Luisa M Sastre, MD, PhD, Specialist Ophthalmologist in Medical Retina, to its Dubai-based team of medical specialists.
The hospital said Dr Sastre is a highly experienced Ophthalmologist with a special interest in retinal diseases and especially diabetes-related disorders, who has performed many intravitreal injections for diabetes patients and a large number of surgeries for cataract patients, as well as other procedures such as pterygium and minor lid surgeries. She is also experienced in treating children and in the treatment of other eye diseases such as glaucoma.
Dr Sastre has held several posts as a Consultant Ophthalmologist and as an Intensive Care Specialist in private and public hospitals in Madrid, Spain, before relocating to Dubai. She has also undertaken medical teaching and charitable activities related to her clinical work.
Moorfields Eye Hospital Dubai (MEHD) is the first overseas branch of Moorfields Eye Hospital NHS Foundation Trust, the oldest and one of the largest centres for ophthalmic treatment, teaching and research in the world. MEHD is located at the Al Razi Medical Complex in Dubai Health Care City. It provides day case surgery and outpatient diagnostic and treatment services, for a variety of surgical and non-surgical eye conditions.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies